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ABSTRACT
Objective The interleukin 2 (IL-2) and interleukin 21
(IL-21) locus at chromosome 4q27 has been associated
with several autoimmune diseases, and both genes are
related to immune system functions. The aim of this
study was to evaluate the role of the IL-2/IL-21 locus in
systemic sclerosis (SSc).
Patients and methods The case control study
included 4493 SSc Caucasian patients and 5856 healthy
controls from eight Caucasian populations (Spain,
Germany, The Netherlands, USA, Italy, Sweden, UK and
Norway). Four single nucleotide polymorphisms
(rs2069762, rs6822844, rs6835457 and rs907715) were
genotyped using TaqMan allelic discrimination assays.
Results We observed evidence of association of the
rs6822844 and rs907715 variants with global SSc
(pc=6.6E-4 and pc=7.2E-3, respectively). Similar
statistically signiﬁcant associations were observed for the
limited cutaneous form of the disease. The conditional
regression analysis suggested that the most likely genetic
variation responsible for the association was the
rs6822844 polymorphism. Consistently, the rs2069762A-
rs6822844T-rs6835457G-rs907715T allelic combination
showed evidence of association with SSc and limited
cutaneous SSc subtype (pc=1.7E-03 and pc=8E-4,
respectively).
Conclusions These results suggested that the IL-2/IL-21
locus inﬂuences the genetic susceptibility to SSc.
Moreover, this study provided further support for the
IL-2/IL-21 locus as a common genetic factor in
autoimmune diseases.
INTRODUCTION
Interleukin 2 (IL-2) and interleukin 21 (IL-21) are
equally attractive biological candidates that may
inﬂuence the pathogenesis of autoimmune diseases.
Both are cytokines involved in the proliferation of
T and B lymphocytes and different immunological
activation pathways.1 Moreover, the IL-2 and IL-21
genes cover a region of approximately 200 kb that
maps in the 4q27 locus. IL-2 has an important role in
the maintenance of immune system homeostasis
and self-tolerance. This cytokine has two paradoxical
roles: promoting T cell proliferation and terminating
Tcell responses. Moreover, IL-2 facilitates the produc-
tion of immunoglobulins through B cells and induces
the differentiation and proliferation of natural killer
cells.1 2 IL-21 is a potent immunomodulatory cyto-
kine with pleiotropic effects on both innate and
adaptive immune responses. These actions include
the following positive effects: enhanced proliferation
of lymphoid cells, increased cytotoxicity of CD8 T
cells and natural killer cells, and differentiation of B
cells into plasma cells. IL-21 is also produced by T
helper 17 (Th17) cells and is a critical regulator of
Th17 development.1 3 Genetic association studies
have demonstrated that several IL-2/IL-21 poly-
morphisms inﬂuence the risk for autoimmune dis-
eases (AIDs). The ﬁrst evidence of this association
was found in type 1 diabetes, Graves’ disease, coeliac
diseases and rheumatoid arthritis.4–7 These results
have been conﬁrmed through replication studies in
different populations and extended to other auto-
immune diseases, such as inﬂammatory bowel dis-
eases, giant cell arthritis, psoriasis and systemic
lupus erythematosus (SLE).8–17
Systemic sclerosis (SSc) is a chronic ﬁbrotic auto-
immune disease in which patients are commonly
classiﬁed into the following two major subgroups
that are related to the speciﬁc autoantibodies against
several nuclear and/or nucleolar antigens: (i) limited
cutaneous SSc (lcSSc), which is related to the posi-
tive status of anticentromere autoantibodies (ACA)
and (ii) diffuse cutaneous (dcSSc), which is related
to the positive status of antitopoisomerase
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autoantibodies (ATA).18–22 More than 40 susceptibility loci to SSc
have been identiﬁed during the last 10 years. Half of these variants
need to be replicated in different populations and many of these
variants are shared among different AIDs, especially SLE.22–25 In
this regard, one single nucleotide polymorphism (SNP) of the IL-2
gene was proposed as risk factor to lcSSc subtype,26 but this asso-
ciation has not been conﬁrmed by other studies. Moreover the
IL-21 gene has been implicated as a potential driver of AIDs and
recently a ﬁne-mapping in SLE demonstrated that variants of the
IL-2/IL-21 region are implicated in the genetic susceptibility to
SLE.12 16 Thus, the aim of this study was to evaluate the inﬂuence
of the IL-2/IL-21 region in SSc genetic susceptibility.
PATIENTS AND METHODS
Subjects
This case-control association study was comprised of 4493 SSc
patients and 5896 controls of Caucasian ancestry. The discover
cohort included the Spanish group, which consisted of 1176
SSc patients and 1721 healthy controls. The follow-up phase
consisted of the following subjects: 609 SSc cases and 426 con-
trols from Germany, 365 SSc cases and 734 controls from the
Netherlands, 916 SSc cases and 884 controls from USA, 595
SSc cases and 1107 controls from Italy, 225 SSc cases and 273
controls from Sweden, 374 SSc cases and 436 controls from the
UK and 102 SSc cases and 278 controls from Norway. There
was an overlapping of 1726 SSc and 2578 controls with the pre-
vious GWAS in SSc.25 The patients fulﬁlled the 1980 American
College of Rheumatology classiﬁcation criteria for SSc27 or the
criteria proposed for early SSc.21 In addition, the patients were
classiﬁed as having lcSSc or dcSSc as described by LeRoy et al.21
The following clinical data were collected for the ascertainment
of the clinical phenotype of the SSc patients: age, gender and
presence of SSc-speciﬁc autoantibodies (Ab; ACA and ATA).
The control population consisted of unrelated healthy indivi-
duals recruited in the same geographical regions as the SSc
patients, and they were matched by age, sex and ethnicity
with the SSc patient groups. The study was approved by local
ethical committees from all the participating centres. Both
patients and controls were included in the study after written
informed consent was obtained.
SNP Selection and genotyping
Four SNPs of the IL-2/IL-21 region were selected for this study.
The rs2069762 SNP was selected because it has been suggested
to be a genetic factor of lcSSc subtype susceptibility by a study
in a small Italian cohort.26 SSc and SLE share some immunoge-
netic pathways; thus, the rs6822844, rs6835457 and rs907715
IL-2/IL-21 polymorphisms were studied because they are the
most associated variants in a recent ﬁne-mapping of the region
in SLE.12
DNA from the patients and the controls were extracted from
peripheral white blood cells following standard procedures. The
samples were genotyped for the rs2069762, rs6822844, rs6835457
and rs907715 IL-2/IL-21 region polymorphisms using predesigned
SNP genotyping assays from Applied Biosystems (Assay IDs:
C__15859930_10, C__28983601_10, C___1597475_10 and
C___8949748_10, respectively). TaqMan SNP genotyping was per-
formed using a 7900HT Real-Time PCR system from Applied
Biosystems following the manufacturer’s suggestions (Foster City,
California, USA). In all the cohorts, the genotyping success rate
was greater than 95%, and randomly selected samples were geno-
typed twice to verify the genotyping accuracy. Ninety-nine per
cent of the genotypes were identical.
Statistical analysis
The Hardy-Weinberg equilibrium was tested for all the SNPs in
all the studied populations. Signiﬁcance was calculated using
2×2 contingency tables and Fisher ’s exact test or the χ2 test
when necessary to obtain p values, ORs and 95% CIs using
PLINK (V.1.07) software (http://pngu.mgh.harvard.edu/purcell/
plink/).28 The p values less than 0.05 were considered to
be statistically signiﬁcant. The Bonferroni correction was
applied to the signiﬁcant p values and referred in the text as
pc (pcorrected). Cochran-Mantel-Haenszel meta-analysis was per-
formed to control the differences among populations as imple-
mented by the PLINK software. In addition, the Breslow-Day
test (BD test) and the Higgins’ test (I2) were performed using
the PLINK software in each meta-analysis. The random-effects
model was checked in the signiﬁcant BD Pvalues analysis. The
dependency of the association between each SNP and every
studied genetic variant was determined by a conditional logistic
regression analysis (considering the different cohorts as covari-
ates) using the PLINK software. Linkage disequilibrium (LD)
patterns between the four studied SNPs were estimated by the
expectation-maximisation algorithm using HAPLOVIEW (V.4.2;
Broad Institute of MIT and Harvard) and PLINK software. To
evaluate the allelic combination difference between cases and
controls, the conditional haplotype-based associations test was
applied using the PLINK software.29 The statistical power of
the combined analysis was between 91% and 99% for all the
SNPs, allowing for the detection of associations with an OR
equal to 1.2 at a 5% signiﬁcance level and the lowest minor
allelic frequency, according to the Power Calculator for Genetic
Studies 2006 software, which uses the methods described by
Skol et al.30
RESULTS
The cases and controls of the eight Caucasian populations
were in Hardy-Weinberg equilibrium at a 5% signiﬁcance level.
Additionally, the minor allelic frequencies of the four studied
SNPs were similar to those reported by the HapMap project
for the Utah residents with ancestry from northern and western
Europe (CEU) population (http://hapmap.ncbi.nlm.nih.gov/).
The LD structure of the eight cohorts is shown in the supple-
mental material (see online supplementary ﬁgure S1).
First, an association study was conducted in a Spanish case-
control set, and a signiﬁcant association was observed between
the rs907715 SNPs minor allele and the global SSc (pc=0.03,
OR=0.85 95% CI 0.8 to 0.9) and the lcSSc subtype (pc=0.04,
OR=0.83 95% CI 0.7 to 0.9). A trend of association was
observed between the minor allele of the rs6822844 SNP and
the global SSc (pvalue=0.04, OR=0.84 95% CI 0.7 to 1) and
lcSSc subtype (pvalue=0.04, OR=0.79 95% CI 0.7 to 0.9). Also
a trend of association was detected between the minor allele of
rs6835457 and lcSSc subtype in this population (pvalue=0.03,
OR=0.87 95% CI 0.8 to 1). In contrast, no association was
observed with the rs2069762 SNP (pvalue=0.8 for both SSc and
lcSSc) (see online supplementary tables S1–S3). Based on these
observations, we decided to evaluate other Caucasian cohorts
and to perform a meta-analysis.
Table 1 shows the meta-analysis results for the IL-2/IL-21
SNPs, the global SSc, the main SSc subtypes, the ACA and
the ATA antibodies positive status. The combined analysis
showed that the minor allele frequencies of the rs6822844
and rs907715 SNPs were signiﬁcantly higher in controls
than in SSc (pc=6.6E-04 OR=0.86 95% CI 0.79 to 0.93 and
pc=7.2E-3 OR=0.91 95% CI 0.85 to 0.96, respectively)
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and lcSSc patients (pc=6E-4 OR=0.84 95% CI 0.76 to 0.92
and pc=0.01 OR=0.9 95% CI 0.84 to 0.96, respectively).
A trend of association was observed in the meta-analysis for
the rs6822844 and rs6835457 variants and ACA positive
status (pvalue=0.01 OR=0.87 95% CI 0.78 to 0.97 and
pvalue=0.05 OR=0.92 95% CI 0.85 to 1, respectively). The
rs6835457 SNP also had a trend of association with global
SSc and lcSSc (pvalue=0.01 OR=0.93 95% CI 0.87 to 0.98 and
Table 1 Genotype and minor allele frequencies of meta-analysis of four IL-2/IL-21 SNPs located in SSc patients and healthy controls from European
and US populations
Genotype, N (%) Allele test
SNP 1/2 Subgroup (N) 1/1 1/2 2/2 MAF (%) p Value* pc† OR (CI 95%)‡
rs2069762 C/A Controls (n=5482) 510 (9.30) 2266 (41.34) 2706 (49.36) 29.97
SSc (n=4281) 429 (10.02) 1778 (41.53) 2074 (48.45) 30.79 0.08 NA 1.06 (0.99 to 1.13)
lcSSc (n=2897) 295 (10.18) 1203 (41.53) 1399 (48.29) 30.95 0.09 NA 1.06 (0.99 to 1.14)
dcSSc (n=1384) 134 (9.68) 575 (41.55) 675 (48.77) 30.46 0.31 NA 1.05 (0.96 to 1.15)
ACA+ (n=1736) 170 (9.79) 730 (42.05) 836 (48.16) 30.82 0.25 NA 1.05 (0.97 to 1.14)
ATA+ (n=1031) 94 (9.12) 428 (41.51) 509 (49.37) 29.87 0.98 NA 1.00 (0.90 to 1.11)
rs6822844 T/G Controls (n=5792) 149 (2.57) 1475 (25.47) 4168 (71.96) 15.31
SSc (n=4407)** 98 (2.22) 996 (22.60) 3313 (75.18) 13.52 1.7E-04 6.6E-04 0.86 (0.79 to 0.93)
lcSSc (n=2977)*** 67 (2.25) 659 (22.14) 2251 (75.61) 13.32 1.5E-04 6.0E-04 0.84 (0.76 to 0.92)
dcSSc (n=1430) 31 (2.17) 337 (23.57) 1062 (74.27) 13.95 0.06 NA 0.89 (0.79 to 1)
ACA+ (n=1763) 38 (2.16) 395 (22.40) 1330 (75.44) 13.36 0.01 0.06 0.87 (0.78 to 0.97)
ATA+ (n=1074) 29 (2.70) 257 (23.93) 788 (73.37) 14.66 0.67 NA 0.97 (0.85 to 1.11)
rs6835457 G/A Controls (n=5720) 668 (11.68) 2507 (43.83) 2545 (44.49) 33.59
SSc (n=4392)**** 445 (10.13) 1908 (43.44) 2039 (46.43) 31.85 0.013 0.05 0.93 (0.87 to 0.98)
lcSSc (n=2965)***** 312 (10.52) 1255 (42.33) 1398 (47.15) 31.69 0.014 0.06 0.92 (0.86 to 0.98)
dcSSc (n=1427) 133 (9.32) 653 (45.76) 641 (44.92) 32.20 0.28 NA 0.95 (0.87 to 1.04)
ACA+ (n=1765) 186 (10.54) 756 (42.83) 823 (46.63) 31.95 0.12 NA 0.94 (0.86 to 1.02)
ATA+ (n=1064) 113 (10.62) 481 (45.21) 470 (44.17) 33.22 0.99 NA 1.00 (0.90 to 1.10)
rs907715 T/C Controls (n=5644) 670 (11.87) 2491 (44.14) 2483 (43.99) 33.94
SSc (n=4341)****** 437 (10.07) 1883 (43.38) 2021 (46.56) 31.76 1.8E-03 7.2E-03 0.91 (0.85 to 0.96)
lcSSc (n=2929)******* 307 (10.48) 1236 (42.20) 1386 (47.32) 31.58 2.7E-03 0.01 0.90 (0.84 to 0.96)
dcSSc (n=1412) 130 (9.21) 647 (45.82) 635 (44.97) 32.12 0.14 NA 0.93 (0.85 to 1.02)
ACA+ (n=1744) 180 (10.32) 754 (43.23) 810 (46.44) 31.94 0.05 NA 0.92 (0.85 to 1)
ATA+ (n=1056) 109 (10.32) 475 (44.98) 472 (44.70) 32.81 0.48 NA 0.96 (0.87 to 1.07)
*All p values have been calculated for the allelic model.
**Breslow-Day pvalue=0.29. Higgins’ test (I
2)=17.3%. Random-effects model pvalue=8.8E-04 pc=3.5E-3 Random-effects OR=0.86.
***Breslow-Day pvalue=0.16. I
2=33.9%. Random-effects model pvalue=4.1E-03. Random-effects OR=0.84.
****Breslow-Day pvalue=0.06. I
2=48.6%. Random-effects model pvalue=0.1. Random-effects OR estimate=0.93.
*****Breslow-Day pvalue=0.09. I
2=43.4%. Random-effects model pvalue=0.11. Random-effects OR estimate=0.92.
******Breslow-Day pvalue=0.02. I
2=58%. Random-effects model pvalue=0.08. Random-effects OR estimate=0.91.
*******Breslow-Day pvalue=0.09. I
2=43.7%. Random-effects model pvalue=0.05. Random-effects OR estimate=0.91.
†If it is applicable, Bonferroni correction is shown.
‡OR for the minor allele.
ACA, anticentromere autoantibodies; ATA, antitopoisomerase autoantibodies; dcSSc, diffuse cutaneous SSc; NA, not applicable; SNP, single nucleotide polymorphisms;
SSc, systemic sclerosis.
Table 2 Conditional logistic regression analysis for the IL-2/IL-21 SNPs located in SSc considering the eight European and US populations as
covariate
r2 with rs6822844
Group of
analysis SNP
MAF
Cases
MAF
Controls
p value of each SNP
conditioned by rs6822844
p value of rs6822844
conditioned by each SNP Spain Germany
The
Netherlands USA Italy Sweden UK Norway
SSc
rs2069762 0.31 0.30 0.69 1.30E-03 0.06 0.06 0.09 0.07 0.07 0.11 0.06 0.09
rs6835457 0.32 0.34 0.43 0.024 0.25 0.37 0.38 0.36 0.28 0.48 0.37 0.49
rs907715 0.32 0.34 0.19 0.026 0.26 0.37 0.39 0.36 0.29 0.39 0.37 0.49
lcSSc
rs2069762 0.31 0.30 0.69 9.07E-04 – – – – – – – –
rs6835457 0.32 0.34 0.53 0.014 – – – – – – – –
rs907715 0.32 0.34 0.3 0.015 – – – – – – – –
ACA+
rs2069762 0.31 0.30 0.64 0.015 – – – – – – – –
rs6835457 0.32 0.34 0.81 0.061 – – – – – – – –
rs907715 0.32 0.34 0.56 0.063 – – – – – – – –
ACA, anticentromere autoantibodies; lcSSC, limited cutaneous SSc; MAF, minor allelic frequencies; SNP, single nucleotide polymorphisms; SSc, systemic sclerosis.
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pvalue=0.01 OR=0.92 95% CI 0.86 to 0.98, respectively). We
did not detect any signiﬁcant association between the
rs6835457 or rs2069762 SNPs and the global SSc diseases or
its different phenotypes (for detailed information see supple-
mentary tables S1 through S3). It is worth noting that the
minor I2 percentage was observed in the meta-analysis for the
rs6822844 SNP with SSc (17.3%) and lcSSc (33.9%), suggest-
ing that the variation between the populations is moderate.
Moreover, these analyses were the only ones that remained
signiﬁcant in the random-effect model (rs6822844 and SSc
pc=3.5E-3, rs6822844 and lcSSc pc=0.016).
A conditional logistic regression analysis was used to identify
which SNP could be the causal SNP for the observed associa-
tions between the studied polymorphisms. The association of
each SNP was evaluated using the populations as covariates,
and the association was conditioned to the rs6822844 SNP
because the lowest pvalue and strongest effect (OR) were
observed in this locus. Pairwise conditional analysis showed
that the association of the rs907715 SNP was explained by the
rs6822844 effect, because only the latter SNP remained signiﬁ-
cant after conditioned to each other (rs907715 conditioned
pvalue=0.19; rs6822844 conditioned pvalue=0.026). Moreover,
the rs2069762 and rs6835457 SNPs exhibited signiﬁcance only
when conditioned to the rs6822844 SNP. These results sug-
gested that the rs6822844 signal could explain the association
observed in the IL-2/IL-21 locus (table 2).
Finally, the results of the conditional haplotype-based associ-
ation testing are shown in table 3. The allelic combination
formed by the rs2069762 major allele and the rs6822844,
rs6835457 and rs907715 minor alleles was signiﬁcantly
increased in the controls compared with the global SSc
(pc=1.7E-3, OR=0.89 95% CI 0.81 to 0.98), the lcSSc subtype
(pc=8E-4, OR=0.86 95% CI 0.77 to 0.96) and the ACA positive
status (pc=2.7E-2, OR=0.86 95% CI 0.75 to 0.98).
Interestingly, the OR observed for this analysis was not differ-
ent from the one observed in the allelic test. Moreover, the
signiﬁcant effect of the omnibus analyses for SSc, lcSSc and
ACA positive status disappeared when they were controlled
by the rs6822844 SNP (pvalues of the likelihood ratio test
were: pvalue=0.66 for global SSc, pvalue=0.74 for lcSSc and
pvalue=0.93 for ACA+).
DISCUSSION
Our study suggests for the ﬁrst time the inﬂuence of
the rs6822844 polymorphism of the IL-2/IL-21 region in suscep-
tibility to SSc. This variant also inﬂuences the lcSSc subtype of
the diseases and probably the ACA positive status due to the
trend of association observed between the rs6822844 poly-
morphism and this phenotype. Although, our study had sufﬁ-
cient statistical power for both dcSSc and ATA analysis (95%
and 91%, respectively), we observed that there were not signiﬁ-
cant associations between the four IL-2/IL-21 SNPs and dcSSc
or ATA positive status. The ORs exhibited the same direction
as the signiﬁcant associations with SSc and lcSSc, suggesting
that an increment in the sample size with future studies could
show a signiﬁcant relation between the IL-2/IL-21 SNPs and
dcSSc or ATA. Interestingly, the rs6822844 variant was asso-
ciated in the same OR direction as that observed in SLE. The
minor allele of this variant is more frequent in healthy donors
than in SSc patients, lcSSc subtype subjects and SLE
patients.12 16 The logistic regression and the allelic combination
analyses support that the rs6822844 SNP association was
responsible for the observed associations. The rs2069762A-
rs6822844T-rs6835457G-rs907715T allelic combination was
associated as a protective factor to SSc, lcSSc subtype and ACA
positive status, which is the same effect observed for the T
allele of the rs6822844. Importantly, the ORs observed for this
allelic combination were not different from the ORs observed
for the rs6822844 SNP analysis. These observations were
slightly different from the results of the SLE study performed
by Hughes et al12 where the observed association between
IL-2/IL-21 region and SLE could be explained by the rs6835457
and rs907715 SNPs. Together, these results support the idea
that the common genetic factors in autoimmune diseases may
be associated at a regional level but differ in the speciﬁc SNPs
associated with each disease, including the magnitude and dir-
ection of the association.31 32 Although, the logistic regression
test and the allelic combination analyses conditioned by the
rs6822844 SNP suggest that this variant is responsible for the
association observed in the region; we cannot totally discard
a slight role of the rs6835457 and rs907715 polymorphisms
in SSc due to the moderate LD between them and the
r6822844 SNP.
The rs6822844 and rs6835457 SNPs are located in the
ﬂanking 3′-untranslated region of IL-21, and the rs907715 poly-
morphism is located in intron 3 of the IL-21 gene. In contrast,
the rs2069762 SNP is located in the ﬂanking 5′-untranslated
region of IL-2, which did not exhibit signiﬁcant association
with SSc, the subtypes of the disease or the antibodies’ status.
The rs2069762 minor allele has been previously associated with
the lcSSc subtype.26 Our study has a considerably larger sample
size than the previous study; therefore the previously reported
Table 3 Conditional haplotype-based association analysis of four IL-2/IL-21 SNPs located according to diseases, lcSSc diseases subtype and ACA
status and considering the eight European and US populations as covariate
Frequency Frequency Frequency
Allelic
combination† Controls SSc OR (CI 95%) P* Pc‡ lcSSc OR (CI 95%) P* Pc‡ ACA+ OR (CI 95%) P* Pc‡
AGGT 0.182 0.181 -ref- –** – 0.181 -ref- –*** – 0.183 -ref- –**** –
ATGT 0.152 0.133 0.89 (0.81 to 0.98) 4.12E-04 1.65E-03 0.131 0.86 (0.77 to 0.96) 2.01E-04 8.04E-04 0.132 0.86 (0.75 to 0.98) 6.81E-03 2.72E-02
CGAC 0.298 0.306 1.04 (0.96 to 1.12) 0.18 NA 0.308 1.03 (0.94 to 1.13) 0.2 NA 0.308 1.02 (0.92 to 1.14) 0.27 NA
AGAC 0.369 0.379 1.04 (0.96 to 1.13) 0.1 NA 0.38 1.03 (0.94 to 1.13) 0.12 NA 0.377 1.02 (0.91 to 1.13) 0.4 NA
†The order of the SNPs is rs2069762, rs6822844, rs6835457, rs907715.
*pvalue of the likelihood ratio test. Based on WHAP method.
29
‡If it is applicable, Bonferroni correction is shown. Not applicable (NA).
**Omnibus test X2=14.5 (df=3); p value=2.35E-03; Pc=9.4E-03.
***Omnibus test X2=14.5 (df=3); p value=2.32E-03; Pc=9.28E-03.
****Omnibus test X2=8.92 (df=3); p value=0.03; Pc=0.12.
ACA, anticentromere autoantibodies; lcSSc, limited cutaneous SSc; SNP, single nucleotide polymorphisms; SSc, systemic sclerosis.
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signiﬁcant association for rs2069762 might stem from type 1
statistical error. This fact together with the location of the
associated SNP suggests a highlighted role of the IL-21 cyto-
kine. By examining the expression and regulation of IL-21 and
the IL-21 receptor (IL-21R) in patients with SSc, a previous
study demonstrated an upregulation of IL-21R in epidermis
samples.33 However, a recent study has demonstrated that the
scleroderma burden in allogeneic haemopoietic stem cell trans-
plantations is driven by Th17 induction via IL-21 and IL-23 sig-
nalling.34 Together, these results suggest that IL-21/IL-21R
signalling has a pathogenic function in SSc.
The role of IL-2 and IL-21 in the immune system makes
these genes plausible candidates for the genetic component of
autoimmune diseases.1 35 36 Our results increase the evidence
that have showed that the rs6822844 is signiﬁcantly associated
with multiple autoimmune diseases.10–13 According to the
HapMap project for the CEU population (http://hapmap.ncbi.
nlm.nih.gov/), the rs682284 polymorphism tags seven other
variants located along the IL-2/IL-21 region (rs13132245,
rs13122573, rs4459999, rs13151961, rs13140464, rs6814280
and rs2069778), but clear evidence that connects any of these
variants with the IL-2 and/or IL-21 regulation is lacking.
Together, all point out these genetic variants as good candidates
for functional studies in SSc pathogenesis and in other auto-
immune diseases.
Although, the combined analyses of the rs6822844 poly-
morphism did not show heterogeneity (BD pvalue=0.29.
I2=17.3%) between the eight European populations, a weak
point of our study is that we did not have enough data available
to control the association by principal component. Furthermore,
as we mentioned before, an increment in the sample size for
the stratiﬁed analysis could deﬁne in an accurate way the role
of the studied variants in different clinical manifestations of
SSc as their inﬂuence in the presence of coautoimmunity.
Consequently, it is necessary to replicate the actual observation.
To conclude, consistent with previous studies on auto-
immune diseases, the IL-2/IL-21 region is a susceptibility
genetic factor for SSc and its lcSSc subtype. The rs6822844
polymorphism confers the best association signal for SSc. It is
also worth mentioning that this study shows the importance
of the study of different populations and broad collaboration to
ﬁnd the missing heritability for relatively rare diseases like SSc.
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